Serum levels of soluble CD26 and CD30 in patients on hemodialysis

被引:21
|
作者
Nakao, K [1 ]
Nagake, Y [1 ]
Okamoto, A [1 ]
Ichikawa, H [1 ]
Yamamura, M [1 ]
Makino, H [1 ]
机构
[1] Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan
关键词
soluble CD26; soluble CD30; hemodialysis; Th1; Th2; hemodialysis duration;
D O I
10.1159/000058395
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Various abnormalities of the immune system have been demonstrated in patients on hemodialysis (HD). We hypothesize that the imbalance between type I helper T (Th1) cells and-type 2 helper T (Th2) cells in patients on HD contributes to these abnormalities. Furthermore, we investigate the relationship between the. Th1/Th2 imbalance and HD duration. Methods:We measured the serum levels of soluble CD26 (sCD26) and soluble CD30 (sCD30) in 47 patients on-HD and in 13 patients with chronic renal failure not on HD and analyzed. the effect of HD duration on the serum levels of sCD26 sCD30. Results: The serum level of sCD26 in the HD group was significantly lower than that in the control group. On the other-hand, the serum levels of sCD30 in the HD group and in the CRF group were significantly higher than in the control group. I-In the short-term HD group (< 1 year), the serum levels of sCD26 were lower and the sCD30 levels higher than those in middle-term HD group (1-10 years). Conclusions: In the HD group, the Th1/Th2 balance may shift towards Th2 dominance. It is possible that this imbalance contributes to the abnormality of the immune system in HD patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 50 条
  • [1] Soluble CD26 and CD30 in Patients with Brucellosis
    Rafiei, A.
    Roushan, M. R. Hasanjani
    Ajami, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E214 - E214
  • [2] Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis
    Ulusoy, Hasan
    Kamanli, Ayhan
    Ilhan, Necip
    Kuru, Omer
    Arslan, Sule
    Alkan, Gokhan
    Ozgocmen, Salih
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (12) : 3857 - 3862
  • [3] Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis
    Hasan Ulusoy
    Ayhan Kamanli
    Necip Ilhan
    Omer Kuru
    Sule Arslan
    Gokhan Alkan
    Salih Ozgocmen
    Rheumatology International, 2012, 32 : 3857 - 3862
  • [4] Soluble CD26 and CD30 Levels in Patients With Common Variable Immunodeficiency
    Mahmoudi, M.
    Hedayat, M.
    Aghamohammadi, A.
    Rezaei, N.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2013, 23 (02) : 120 - 124
  • [5] Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis
    Ajdary, Soheila
    Jafari-Shakib, Reza
    Riazi-Rad, Farhad
    Khamesipour, Ali
    JOURNAL OF INFECTION, 2007, 55 (01) : 75 - 78
  • [6] Soluble CD26 and CD30 levels in CSF of patients with relapsing neuromyelitis optica
    Misu, T
    Fujihara, K
    Narikawa, K
    Nakashima, I
    Sato, S
    Itoyama, Y
    NEUROLOGY, 2004, 62 (07) : A380 - A381
  • [7] Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica
    Narikawa, K
    Misu, T
    Fujihara, K
    Nakashima, I
    Sato, S
    Itoyama, Y
    JOURNAL OF NEUROLOGY, 2006, 253 (01) : 111 - 113
  • [8] Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica
    K. Narikawa
    T. Misu
    K. Fujihara
    I. Nakashima
    S. Sato
    Y. Itoyama
    Journal of Neurology, 2006, 253 : 111 - 113
  • [9] Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia
    Wang, Honghui
    Gu, Xueping
    Li, Huiyuan
    Yin, Lingmei
    Tao, Wei
    Yu, Jingxing
    Zhou, Qiyuan
    Mu, Hongli
    Shen, Yu
    Yao, Jin
    Liu, Lin
    Bi, Hui
    Yang, Renchi
    Zhou, Zeping
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [10] Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity
    Ajdary, S.
    Riazi-Rad, F.
    Jafari-Shakib, R.
    Mohebbali, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 145 (01): : 44 - 47